|
|
ZymoGenetics, Inc. - Company Profile Snapshot
| Company Profile: |
ZymoGenetics, Inc. |
| Ticker: |
ZGEN |
| Exchanges: |
NAS |
| 2007 Sales: |
38,477,000 |
| Major Industry: |
Drugs, Cosmetics & Health Care |
| Sub Industry: |
Ethical Drug Manufacturers |
| Country: |
UNITED STATES |
| Employees: |
570 |
Business Description
ZymoGenetics, Inc.. The Company's principal activity is to discover, develop, manufacture and market therapeutic protein-based products for the treatment of human diseases. The Company's focus is in the areas of hemostasis, inflammatory, and autoimmune diseases, cancer and viral infection. The Company has generated proprietary product candidates and commercializes them through internal development, collaborations with biopharmaceutical partners or out-licensing of patents. The Company has developed six recombinant protein products namely Novolin(R), NovoSeven(R), Regranex(R), GEM 21S, GlucaGen(R) and Cleactor(TM), which it derives royalties except for NovSeven and NovoRapid. The products are marketed by Novo Nordisk, Johnson & Johnson, BioMimetic Therapeutics Inc., and Eisai Co. Ltd. The Company has also out-licensed several products to third parties in return for milestone payments and royalties.
|
Not the Report you are looking for? Click here for more browsing options.
|
The following information is available to subscribers or can be accessed by purchasing the Company Profile Report:
|
- Address (mailing), Phone Number, Web Address
- Earnings/Dividends
- Employees
- Exchanges Listed
- Financial Ratio Analysis |
- Recent Stock Performance
- Sales (recent year)
- Senior Officers
- Shareholder Information
- Stock Analysis Summary |
Layout and Content of a Typical Report
|
|
|
|
|
